bi-907828
boehringer ingelheim
['bi 907828', 'solid tumor']
#icymi published at #asco23 the mdm2 p53 antagonist bi 907828 in patients with advanced or #metastatic solid tumors: results of a phase ia, first-in-human, dose-escalation study. 
Follow Cancer Discovery for high-impact articles and news covering major advances in basic, translational, and clinical cancer research. Published by @AACR.